1月15日 - ** 制药商OcugenOCGN.O的股价盘前上涨2.7%至1.93美元
** 该公司称 (link) 实验性疗法 OCU410 可减缓地理萎缩（一种严重的老年性黄斑变性）的发展速度
** 约半数接受治疗的患者眼部病变的生长速度比未接受治疗的患者降低了 46%，而中等剂量的患者眼部病变的生长速度降低了 54% - OCGN
** 补充说，在这项有 51 名患者参加的中期试验中，没有发现严重的副作用。
** 计划在 2026 年进行更大规模的后期试验；目标是在 2028 年向监管部门提交申请
** 截至上次收盘，股价在过去一年中上涨了约 68%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.